Skip to main content
OpenTrials
Completed

NCT Number: NCT04543474

Treatment Efficacy of Low FODMAP Versus Low Lactose Diet in IBS Patients

A low FODMAP diet (LFD) has become a standard treatment in irritable bowel syndrome (IBS) patients. Compliant adherence to a LFD is challenging. The investigator looked at the effect of a LFD compared to a less restrictive low lactose diet (LLD) in a randomized cross-over trial with IBS patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder. It affects 10 - 20% of the adult population. Pharmaceutical therapy as bulking agents, anticholinergics, antispasmodics, and antidiarrheals are mostly unsatisfactory and many gastroenterologists recommend therefore dietary management. Most patients note that various foods elicit abdominal symptoms and therefore restrict their diet .

The low fermentable oligosaccharide, disaccharide, monosaccharide and polyol (FODMAP) diet has currently the greatest evidence for efficacy in IBS. The rationale behind the LFD is the exclusion of poorly absorbed short-chain carbohydrates which would create an osmotic load, drag fluid into the small intestine and would be fermented by the colonic microbiome, both leading to abdominal distention and increased luminal influx. FODMAPs do not cause symptoms in healthy adults as they neither show these abnormalities in gut physiology nor suffer from visceral hypersensitivity .

It is not known however whether change in symptoms is induced by a reduction in all FODMAPs or simply a single component as for example lactose. If there is a lactase deficiency, as it is the case in 2-20% of Central- / Northern Europeans, lactose cannot be hydrolysed and causes the above mentioned symptoms. Many IBS patients avoid lactose, even though only few have a lactase deficiency. Lactose intolerance but not lactase deficiency is more frequent in patients with IBS. The investigator wanted to examine if the demanding LFD is more effective than elimination of lactose alone.

Our study, comparing in detail the effects of low FODMAP versus low lactose diet in IBS patients is a novelty, analysing a clinically highly relevant topic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • functional bowel symptoms as defined by the Rome IV criteria
  • subjective lactose intolerance

Exclusion criteria

  • pharmacologic agents to alter symptoms (laxatives, antidiarrheal agents)
  • smoking
  • antibiotic therapy within the last 4 weeks
  • gastrointestinal diseases (Celiac disease was excluded by negative serologic testing while on a gluten containing diet
  • any type of food allergy

Treatment and study plan

Low Lactose Diet

Other

First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.

Low fodmap diet

Other

First, there was a run-in period (day 1-14), during which patients were randomly assigned by computer-generated bloc randomization to either the LLD or the LFD for 21 days (day 15-35). A dietician educated the participants on the first interventional diet. This phase was followed by a wash-out period of 21 days (day 36-56) with resumption of a normal balanced daily-life diet before crossing over to the alternate interventional diet (day 57-77). There were visits at the end of the washout phase with an instruction on the second interventional diet and at the end of the study.

Primary outcomes

  1. Change from gastrointestinal symptoms in Irritable Bowel Syndrome (IBS symptom severity score) from Baseline to "post intervention diet".

    Time frame: The IBS SSS was assessed at the end of the run in period and at the end of the intervention diets (low lactose and low FODMAP diet) at day 14, 35 and 77.

    The symptom severity score (IBS-SSS) is a validated score to evaluate the severity of an IBS. The five subscores for abdominal pain (severity and frequency), abdominal distension, satisfaction with stool habits and interference of IBS with daily life were each rated on a VAS (visual analogue scale) 0-100 mm scale and added up to a maximal sum of 500. A total score of 75 - 175 was regarded as mild, 175 - 300 as moderate and > 300 as severe IBS.

Secondary outcomes

  1. IBS symptom severity subscore "abdominal pain severity"

    Time frame: IBS subscores were assesses at the end of each trial phase (run-in, first intervention diet, wash-out, second intervention diet) at day 14, 35, 56 and 77.

    The subscore (abdominal pain severity was assessed individually, on a VAS (visual analogue scale) 0-100 mm scale (the less, the better)

  2. IBS- symptom severity subscore "abdominal pain frequency"

    Time frame: IBS subscores were assesses at the end of each trial phase (run-in, first intervention diet, wash-out, second intervention diet) at day 14, 35, 56 and 77.

    The subscore abdominal pain frequency was assessed individually on a VAS (visual analogue scale) 0-100 mm scale (the less, the better)

  3. IBS- symptom severity subscore "abdominal distension"

    Time frame: IBS subscores were assesses at the end of each trial phase (run-in, first intervention diet, wash-out, second intervention diet) at day 14, 35, 56 and 77.

    The subscore abdominal distension was assessed individually on a VAS (visual analogue scale) 0-100 mm scale (the less, the better)

  4. IBS symptom severity subscore "satisfaction with stool habits"

    Time frame: IBS subscores were assesses at the end of each trial phase (run-in, first intervention diet, wash-out, second intervention diet) at day 14, 35, 56 and 77.

    The subscore satisfaction with stool habits was assessed individually on a VAS (visual analogue scale) 0-100 mm scale (the less the better).

  5. IBS symptom severity subscore "interference of IBS with daily life"

    Time frame: IBS subscores were assesses at the end of each trial phase (run-in, first intervention diet, wash-out, second intervention diet) at day 14, 35, 56 and 77.

    The subscore satisfaction with stool habits was assessed individually on a VAS (visual analogue scale) 0-100 mm scale (the less, the better)

  6. IBS symptom severity score

    Time frame: IBS SSS (total) was assessed at the end of the run-in (day 14), and wash-out phase (day 56).

    The symptom severity score (IBS-SSS) is a validated score to evaluate the severity of an IBS. The five subscores for abdominal pain (severity and frequency), abdominal distension, satisfaction with stool habits and interference of IBS with daily life were each rated on a VAS 0-100 mm scale and added up to a maximal sum of 500. A total score of 75 - 175 was regarded as mild, 175 - 300 as moderate and > 300 as severe IBS.

  7. Stool frequency

    Time frame: Stool frequency was assessed daily throughout the study (day 1-77).

    Patients recorded stool frequency

  8. Stool consistency

    Time frame: Stool consistency was assessed daily throughout the study (day 1-77).

    Patients recorded stool consistency according to the Bristol Stool Chart (BSC) Type 1 hard lumps, Type 2 sausage shaped but lumpy, Type 3 sausage with cracks, Type 4 smooth sausage, Type 5 soft blobs, Type 6 fluffy pieces, Type 7 entirely liquid.

  9. Body weight

    Time frame: Body weight was assesses at the beginning of the study (day 1) and at the end of each trial phase (run-in, first intervention diet, wash-out, second intervention diet) at day 14, 35, 56 and 77).

    Body weight in kg.

Sponsors and collaborators

Lead sponsor

Cantonal Hospital of St. Gallen

Other

Registry information

Official study title

Treatment Efficacy of a Low FODMAP Diet Compared to a Low Lactose Diet in IBS Patients: a Randomized, Cross-over Designed Study

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Sep 10, 2020
Registry last updated
Sep 10, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.